Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States

BACKGROUND: Recently released results from a randomized controlled trial have shown that 13-valent pneumococcal conjugate vaccine (PCV13) is efficacious against vaccine-type nonbacteremic pneumonia in adults. OBJECTIVE: We examined the incremental cost-effectiveness of adding PCV13 to the Advisory C...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Gen Intern Med
Huvudupphovsmän: Stoecker, Charles, Kim, Lindsay, Gierke, Ryan, Pilishvili, Tamara
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2016
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4945555/
https://ncbi.nlm.nih.gov/pubmed/26976292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11606-016-3651-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk